Dr. André Marette, PhD
Claim this profileClinical Trials André Marette, PhD is currently running
More about André Marette, PhD
Clinical Trial Related
2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments André Marette, PhD has experience with
- TOTUM-448
Breakdown of trials André Marette, PhD has run
Childhood Obesity
Insulin Resistance
Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does André Marette, PhD specialize in?
André Marette, PhD focuses on Childhood Obesity and Insulin Resistance. In particular, much of their work with Childhood Obesity has involved treating patients, or patients who are undergoing treatment.
Is André Marette, PhD currently recruiting for clinical trials?
Yes, André Marette, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that André Marette, PhD has studied deeply?
Yes, André Marette, PhD has studied treatments such as TOTUM-448.
What is the best way to schedule an appointment with André Marette, PhD?
Apply for one of the trials that André Marette, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.